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Edited by Lev KisselevAbstract All medically useful antibiotics should have the poten-
tial to distinguish between target microbes (bacteria) and host
cells. Although many antibiotics that target bacterial protein
synthesis show little eﬀect on the translation machinery of the
eukaryotic cytoplasm, it is unclear whether these antibiotics
target or not the mitochondrial translation machinery. We
employed an in vitro translation system from bovine mitochon-
dria, which consists of mitochondrial ribosomes and mitochon-
drial elongation factors, to estimate the eﬀect of antibiotics on
mitichondrial protein synthesis. Tetracycline and thiostrepton
showed similar inhibitory eﬀects on both Escherichia coli and
mitochondrial protein synthesis. The mitochondrial system was
more resistant to tiamulin, macrolides, virginiamycin, fusidic
acid and kirromycin than the E. coli system. The present results,
taken together with atomic structure of the ribosome, may pro-
vide useful information for the rational design of new antibiotics
having less adverse eﬀects in humans and animals.
 2005 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Protein synthesis is a multi-step process that includes initia-
tion, elongation, termination and recycling. Each process re-
quires ribosomes, tRNAs and several translation factors. The
ribosome is a universally conserved ribonucleoprotein complex
that catalyzes the ordered polymerization of amino acids direc-
ted by the genetic information on mRNA. Various clinically
useful antibiotics prevent protein synthesis by interacting with
the bacterial ribosome or translation factors. Good antibiotics
do not target the cytoplasmic ribosomes of host cells because
their structures are adapted to ﬁt the structures of bacterial
ribosomes and not those of eukaryotic ribosomes. Mitochon-
drial (mt) ribosomes are categorized as a bacteria-type ribo-
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[7,11,22,31–33]. If antibiotics could penetrate or be transported
into mitochondria, the mt ribosome would be exposed to the
antibiotics, resulting in the inhibition of mt translation.
Aminoglycosides, which target bacterial ribosomes to induce
misreading, are the most commonly used antibiotics. Autotox-
icity is a major irreversible adverse eﬀect of aminoglycosides
and occurs in a dose-dependent fashion [13]. The A1555G
mutation in mt 12S rRNA gene confers susceptibility to
aminoglycosides and can cause non-syndromic deafness
[13,28]. Although the molecular pathogenesis of aminoglyco-
side-induced deafness is not fully understood, it is possible that
aminoglycosides directly bind to the mt rRNA and induce
translation disorders in protein synthesis [15].
Using a modiﬁed fragment reaction (puromycin reaction)
for measuring the peptidyl-transferase activity of the ribo-
somal large subunit, the antibiotic susceptibility of the bovine
mt 39S large subunit was compared to those of Escherichia coli
and bovine cytoplasmic ribosomal subunits many years ago
[11]. The mt large subunit showed low susceptibility to lincos-
amines and macrolides, indicating that the binding sites for
certain of these antibiotics had been altered.
With the advent of an in vitro mt translation system estab-
lished by our group from bovine mitochondria [16,23,34], it
is now possible to characterize several antibiotics with respect
to their abilities to target the small subunit as well as the large
subunit of the mt ribosome. In addition, kirromycin and fusi-
dic acid, which target elongation factors, can also be character-
ized in this system. The present study describes the antibiotic
susceptibility of the mammalian mt translation system.2. Materials and methods
2.1. Materials
E. coli total tRNA was purchased from Boehringer Mannheim. Tet-
racycline, fusidic acid, thiostrepton, kirromycin and virginiamycin M1
were purchased from Sigma–Aldrich. Josamycin, spiramycin, mideca-
mycin acetate were gifts from Meiji seika Co. Ltd. Tiamulin was a gift
from Novartis Co. Ltd, Shanghai, PR China. [14C] phenylalanine was
purchased from Amersham-Pharmacia.
2.2. Preparation of ribosome, elongation factors and aminoacyl-tRNA
The 55S mt ribosome and 70S E. coli ribosome were prepared as de-
scribed previously [16]. Mt EF-G was partially puriﬁed by DEAE–Se-
pharose and Superdex 200 chromotography (Amersham-Pharmacia)
from bovine liver [9]. The concentration of mt EF-G was determined
by quantifying the intensity of the CBB-stained band on a SDS–PAGE
gel by using Fluor-S MAX (Bio-rad). Recombinant E. coli EF-Tu,ation of European Biochemical Societies.
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ﬁed as described [30,40]. The aminoacylation of E. coli tRNA was car-
ried out with an E. coli S100 fraction under the conditions described
previously [23], and protein synthesis was quantiﬁed by measuring
the amount of incorporated [14C] phenylalanine using a scintillation
counter (ALOKA, Liquid Scintillation Counter, LSC-6100).
2.3. Measurement of the inhibition of poly(U)-directed poly(Phe)
synthesis by antibiotics
The in vitro translation was carried out as described in the literature
[16,34] with slight modiﬁcations. Appropriate amounts of antibiotics
and 0.08 lM E. coli ribosomes were pre-incubated for 25 min on ice,
and then at 37 C for 5 min in a buﬀer containing 50 mM Tris–HCl
(pH 7.5), 6.5 mM MgCl2 and 60 mM KCl. Poly(U)-directed polyphe-
nylalanine synthesis by E. coli ribosomes was performed in 20 lL of
the same buﬀer containing 0.08 lM E. coli ribosomes (pre-incubated
with each antibiotic), 0.5 mM GTP, 2 mM DTT, 0.1 mM spermine,
1 mg/ml poly U, 25 mM phosphoenolpyruvate, 2.5 unit/ml pyruvate
kinase, 0.3 lM [14C] Phe-tRNA, 0.6 lM EF-G, 0.6 lM EF-Tu, and
each antibiotic at 37 C for 20 min. Then, 10 lL of the reaction mix-
ture was spotted onto a ﬁlter paper (Whattman 3MM), followed by
deacylation of aminoacyl-tRNA through boiling. The TCA-insoluble
products were then quantiﬁed by liquid scintillation counting
(ALOKA, LSC-6100).
For the mt translation system, the pH of the Tris–HCl buﬀer was
changed to 8.5, and the concentrations of MgCl2, KCl, DTT and
Spermine were changed to 7.5, 5, 1, and 0.5 mM, respectively. All
the other procedures, except for ribosomes, EF-G and EF-Tu, which
were all mitochondrial, were the same as those used in E. coli transla-
tion system. The initial experiments were performed over a wide range
of antibiotic concentrations (0.1 lM to 10 mM) to obtain a rough esti-
mation of the IC50 value for each antibiotic. Based on the results, we
determined the IC50 value for each antibiotic within a narrow rage
of concentrations both in E. coli and mt systems. Each experiment
was repeated at least three times, and the average was taken to be
the ﬁnal IC50 value.
2.4. Site-directed mutagenesis of E. coli ribosomal 23S rRNA
We used E. coli strain NT101 (derived from TA542 [2] which was
kindly provided by Dr. Cathy Squires of Tuft University) which is de-
leted for all chromosomal rRNA operons and, instead, contains a res-
cue plasmid, pRB101, carrying the rrnB and sacB genes. Using a Quick
change site-directed mutagenesis kit (Stratagene), the A2058G point
mutation was introduced into the 23S rRNA gene on another plasmid,
pRB102, which shares the same replication origin (pSC101) as pRB101
but has a diﬀerent antibiotic marker (Km). NT101 cells were trans-
formed with the A2058G mutant plasmid, and colonies resistant to
kanamycin and sucrose were selected to obtain a strain having a ribo-
some with the A2058G mutation.3. Results and discussion
The poly(U)-directed polyphenylalanine synthesis system of
mitochondria was constructed with bovine mt ribosomes, re-
combinant mt EF-Tu and partially puriﬁed mt EF-G from bo-
vine liver mitochondria. The conditions were optimized asTable 1
IC50 values (lM) of various antibiotics in E. coli and mitochondrial systems
Antibiotics Mitochondria E. coli
Tiamulin 58.1 ± 2.6 0.48 ± 0.04
Josamycin 12.3 ± 1.6 0.35 ± 0.04
Spiramycin 24.9 ± 0.5 0.27 ± 0.04
Midecamycin 76.6 ± 1.6 0.43 ± 0.03
Virginiamycin 3.5 ± 0.2 0.22 ± 0.02
Kirromycin 64.9 ± 2.3 0.30 ± 0.02
Fusidic acid 2020 ± 90 33.0 ± 3.0
Thiostrepton 0.60 ± 0.05 0.48 ± 0.02
Tetracycline 170 ± 10 150 ± 10described previously [16,23,34]. As a control system, we em-
ployed the E. coli system which consists of E. coli ribosomes,
recombinant E. coli EF-Tu, and EF-G. Polyphenylalanine
incorporation for 20 min. was plotted against the concentra-
tion of each antibiotic and the IC50 value of each antibiotic
was then added to Table 1.
Tiamulin, a pleuromulin derivative, is known to strongly in-
hibit bacterial translation in vitro and the peptidyl transferase
(PTase) reaction between formylmethionyl (fMet)-tRNA and
puromycin [12,20,27]. The IC50 of tiamulin in the E. coli system
was determined to be 0.48 lM, while the IC50 in the mt system
was 58.1 lM (Fig. 1A and Table 1), which represents nearly a
one hundred-fold diﬀerence. Tiamulin occupies the PTase cen-
ter, and thereby sterically hinders the correct positioning of
tRNA [5,27]. The binding sites of tiamulin at the PTase center
of E. coli 23S rRNA have been assigned as A2058, A2059,
U2506, U2584 and U2585 (according to the E. coli numbering
system) by antibiotic foot-printing [27]. A comparison of the
tiamulin binding sites in E. coli and mt rRNAs, shows that
A2058 is replaced by a G in mitochondria, while all the other
binding sites are conserved. Therefore, the resistance of the
mt system to tiamulin is probably conferred by the base diﬀer-
ence at position 2058 in the mt large subunit rRNA. To conﬁrm
this, we constructed an E. coli ribosome with the A2058G
mutation by site-directed mutagenesis and measured its IC50
value with tiamulin. As expected, the IC50 of the A2058G
E. coli ribosome increased to 18.2 lM. This strongly indicates
that the resistance of the mt system to tiamulin is due to the
presence of a G residue in the mt rRNA binding site.
Macrolide antibiotics are powerful inhibitors of protein syn-
thesis in bacteria [14]. These antibiotics are composed of a
large lactone ring (from 14 to 16 carbon atoms) to which sev-
eral sugars (sometimes amino sugars) are attached. They can
be broadly divided structurally and functionally into relatively
homogenous groups, as represented by the erythromycin and
spiramycin groups [8]. The spiramycin group carries a 16-mem-
bered lactone ring, of which only one position, C5, is frequently
glycosylated with a disaccharide. Macrolide speciﬁcally binds
to the PTase center and to the entrance of the peptide tunnel
in the 50S subunit. It interferes with the interaction of pepti-
dyl-tRNA with the ribosomal P-site, and/or induces a confor-
mational change in the ribosome [4,17,18,29,35].
In the present study, we investigated the susceptibility of
E. coli and mt ribosomes to three 16-membered macrolides,
spiramycin, josamycin and midecamycin. The results (Fig. 1B
and Table 1) clearly indicated that IC50 values for these mac-
rolides are much higher in the mt system than in the E. coli sys-
tem. The main binding sites for these macrolides are certain
bases located within the central loop of domain V of 23SE. coli A2058G Categories Target
18.2 ± 2.3 Pleuromutilin Large subunit
59.5 ± 2.5 Macrolide Large subunit
37.2 ± 0.63 Macrolide Large subunit
78.2 ± 4.6 Macrolide Large subunit





Fig. 1. Inhibition of protein synthesis in mt and E. coli translation systems by antibiotic titration. Inhibition curves for tiamulin (A), midecamycin
(B), kirromycin (C) and fusidic acid (D) are shown. Mitochondria (open square), E. coli wild-type (open circle) and E. coli with the A2058G mutant
ribosome (closed circle).
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to the E. coli numbering system) [8,17,29]. As in the case of
tiamulin, A2058 is known to be one of the most important sites
for macrolide binding. We conﬁrmed that a A2058G mutation
in the E. coli ribosome increases resistance to macrolides by 2
orders of magnitude (Table 1 and Fig. 1B). Taken together
with previous studies [11], our data demonstrate that the resis-
tance of mt ribosomes to macrolides results from a single base
replacement at position 2058 in mt ribosomal RNA.
Virginiamycin occupies both the A and P sites, and thus
blocks two steps in the peptide chain elongation process[18].
This antibiotic also simultaneously induces a conformational
change in the ribosome nearby the PTase center [18]. In our
system, the IC50 values of virginiamycin M1 in the E. coli
and mt systems was determined to be 0.22 and 3.5 lM, respec-
tively. The results suggest that the mt system has slightly greater
resistance to virginiamycin M1 compared to the E. coli system.
Since the binding site of this antibiotic is known to overlap
with that of macrolides [18], resistance to virginiamycin M1
in the mt system might be explained by a similar mechanism
that reduces aﬃnity for both macrolide and virginiamycin
M1 binding.
The elongation factors, EF-G and EF-Tu, interact consecu-
tively with the ribosome during polypeptide synthesis, and
their functions depend on GTP binding and hydrolysis. After
GTP hydrolysis, GDP-bound EF-Tu and EF-G dissociate
from the ribosome. Kirromycin and fusidic acid are antibiotics
that target EF-Tu and EF-G, respectively. Neither kirromycin
nor fusidic acid inhibit GTP hydrolysis by either factor, but
prevent the dissociation of both factors from the ribosome
after GTP hydrolysis [19,24].
Kirromycin inhibits the release of EF-Tu from the ribosome
and freezes the EF-Tu Æ GDP and aminoacyl-tRNA complex
on the ribosome [37,38]. In this study, the IC50 values of kirro-
mycin in the E. coli and mt systems were determined to be 0.30
and 64.9 lM, respectively (Fig. 1C and Table 1). The morethan 200-fold higher value in the mt system suggests that mt
EF-Tu is resistant to kirromycin. In E. coli EF-Tu, several
amino acid residues, such as L120, Q124, Y160, G316, Q329,
A375 and E378, have been reported to be responsible for kir-
romycin resistance [1,24,25]. A comparison of the amino acid
sequences of mt and E. coli EF-Tu revealed that the resistance
of mt translation to kirromycin might be due to F160, V329,
T375 and D378 (according to the E. coli numbering system)
in mt EF-Tu. In fact, it has been reported that E. coli EF-Tu
with the A375T mutation has increased resistance to kirromy-
cin as measured by poly U-directed poly(Phe) synthesis [24].
Fusidic acid, a steroid antibiotic, blocks EF-G Æ GDP on the
ribosome after peptidyl-tRNA translocation and thereby fur-
ther protein synthesis [19]. In our experiment, the IC50 for fu-
sidic acid in mitochondria and E. coli were determined to be
2.02 mM and 33.0 lM, respectively (Fig. 1D). Thus, mt EF-
G displays higher resistance to fusidic acid. Several mutations
in bacterial EF-G that confer resistant to fusidic acid are lo-
cated close to the interface between domains G and 5 of EF-
G [19,21]. It was reported that the IC50 of fusidic acid in
E. coli was increased signiﬁcantly when Ala at position 138
in domain G was replaced with Thr [21], which is identical
to the amino acid at the corresponding position in mt EF-G.
Thiostrepton binds tightly to the GTPase-associated region
of 23S rRNA and inhibits ribosome-associated GTPase events
[3,36,39]. Similar IC50 values for thiostrepton were observed in
E. coli (0.48 lM) and mt (0.60 lM) systems. A1067 is the main
binding site for thiostrepton in this region. In fact, A1067 is
also conserved in mt rRNA.
Tetracycline binds primarily to the 30S ribosome subunit
and blocks the binding of aminoacyl-tRNA to the A site of this
subunit [6,10,26]. The primary binding site is located in the
head of the 30S subunit but another sites are also located in
the body. In mt ribosomes, the bases that form the primary
binding site are slightly diﬀerent from those of E. coli. How-
ever, both E. coli and mt ribosomes had similar IC50 values
6426 L. Zhang et al. / FEBS Letters 579 (2005) 6423–6427for tetracycline. This may be explained by the fact that the
phosphate backbone of rRNA is the main interaction site for
tetracycline. It is known that tetracycline is a group of antibiot-
ics against a wide range of Gram-positive and Gram-negative
bacteria. In addition, bacterial resistance to tetracycline is
usually not acquired by mutations or modiﬁcations in rRNA.
Similar susceptibility to tetracycline found in mt ribosome
can be explained by the unique character of this antibiotic.
It is also important to measure ribosomal susceptibility to
diﬀerent aminoglycosides, which bind the decoding center of
the small subunit to induce misreading. However, the current
in vitro translation cannot be used to test these antibiotic, since
it is impossible to detect misreading by using a homopolymeric
RNA template. Development of an in vitro mt translation
system with non-homopolymeric mRNAs or natural mRNAs
should enable us to resovle this issue.4. Conclusion
We have measured the antibiotic susceptibility of the mt
ribosome and mt elongation factors by measuring IC50 values
for several antibiotics. Although tetracycline and thiostrepton
eﬃciently targeted the mt ribosome, tiamulin, three macrolides
and virginiamycin did not. In addition, mt EF-Tu and mt EF-
G were shown to be resistant to kirromycin and fusidic acid,
respectively. Thus, the mt translation system is substantially
resistant to most but not all antibiotics. Understanding the
molecular basis of these diﬀerences in antibiotic susceptibility
is expected to provide a framework for the development of
new antibiotics for the next generation.
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